Download PDF
TumorDiagnostik & Therapie 2015; 36(05): 272-275
DOI: 10.1055/s-0035-1552188
Schwerpunkt: Prostatakarzinom
Georg Thieme Verlag KG Stuttgart · New York

Übersicht – Aktueller Stand der Systemtherapie beim metastasierten Prostatakarzinom

M. Saar
,
C. H. Ohlmann
Further Information

Publication History

Publication Date:
14 August 2015 (online)

Also available at
    Permissions and Reprints

Patienten mit der Erstdiagnose eines metastasierten Prostatakarzinoms können mit einer alleinigen antiandrogenen Therapie palliativ über viele Jahre in einem stabilen Krankheitszustand bei guter Lebensqualität geführt werden. Allerdings entwickeln diese Patienten im Mittel nach 3–4 Jahren einen erneuten Krankheitsprogress, der mit einem Anstieg des prostataspezifischen Antigens (PSA) einhergeht. Die vorliegende Arbeit gibt eine Übersicht über die aktuellen Therapieoptionen und -sequenzen des metastasierten Prostatakarzinoms.

 

  • Literatur

  • 1 Sweeney C. Impact on overall survival (OS) with chemohormonal therapy versus hormonal therapy for hormone-sensitive newly metastatic prostate cancer (mPrCa): An ECOG-led phase III randomized trial. J Clin Oncol 2014; 32 (Suppl. 05) abstr LBA2
    PubMedGoogle Scholar
  • 2 Ohlmann CH, Duensing S, Eichenauer R et al. Metastasized prostate cancer: Position paper on the use of chemotherapy. Der Urologe Ausg A 2015; in print DOI: 10.1007/s00120-015-3841-0.
    PubMedGoogle Scholar
  • 3 James N. Docetaxel and / or zoledronic acid for hormone-naïve prostate cancer: First overall survival results from STAMPEDE (NCT00268476). J Clin Oncol 2015; 33 suppl: abstr 5001
    PubMedGoogle Scholar
  • 4 Heidenreich A, Bastian PJ, Bellmunt J et al. EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer. Europ Urol 2014; 65: 467-479
    CrossrefPubMedGoogle Scholar
  • 5 Fizazi K, Scher HI, Molina A et al. Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol 2012; 13: 983-992
    CrossrefPubMedGoogle Scholar
  • 6 Ryan CJ, Smith MR, Fizazi K et al. Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study. The Lancet Oncol 2015; 16: 152-160
    CrossrefPubMedGoogle Scholar
  • 7 Scher HI, Fizazi K, Saad F et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. New Engl J Med 2012; 367: 1187-1197
    CrossrefPubMedGoogle Scholar
  • 8 Beer TM, Tombal B. Enzalutamide in metastatic prostate cancer before chemotherapy. New Engl J Med 2014; 371: 1755-1756
    CrossrefPubMedGoogle Scholar
  • 9 Higano C. Response rates and outcomes with enzalutamide for patients with metastatic castration resistant prostate cancer and visceral disease in the PREVAIL-study. Annals Oncol 2014; 25 (Suppl. 04) iv255-iv279
    PubMedGoogle Scholar
  • 10 Tannock IF, de Wit R, Berry WR et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. New Engl J Med 2004; 351: 1502-1512
    CrossrefPubMedGoogle Scholar
  • 11 Kellokumpu-Lehtinen PL, Harmenberg U, Joensuu T et al. 2-Weekly versus 3-weekly docetaxel to treat castration-resistant advanced prostate cancer: a randomised, phase 3 trial. Lancet Oncol 2013; 14: 117-124
    CrossrefPubMedGoogle Scholar
  • 12 Oudard S. TROPIC: Phase III trial of cabazitaxel for the treatment of metastatic castration-resistant prostate cancer. Future Oncol 2011; 7: 497-506
    CrossrefPubMedGoogle Scholar
  • 13 Antonarakis ES, Lu C, Wang H et al. AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer. New Engl J Med 2014; 371: 1028-1038
    CrossrefPubMedGoogle Scholar
  • 14 Angelergues A. Duration of response to androgen-deprivation therapy (ADT) and efficacy of secondary hormone therapy, docetaxel (D), and cabazitaxel (C) in metastatic castration-resistant prostate cancer (mCRPC). J Clin Oncol 2014; 32 (Suppl. 04) abstr 282
    PubMedGoogle Scholar
  • 15 Pezaro CJ, Omlin AG, Altavilla A et al. Activity of cabazitaxel in castration-resistant prostate cancer progressing after docetaxel and next-generation endocrine agents. Europ Urol 2014; 66: 459-465
    CrossrefPubMedGoogle Scholar